Cerner Q1 Profit Beats Estimates; Increases Earnings Outlook

Cerner Corp. (CERN) reported first quarter adjusted EPS of $0.76, up 7% compared to $0.71, last year. On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $0.74, for the quarter. Analysts' estimates typically exclude special items. GAAP EPS was $0.56, up 19% compared to $0.47.

First quarter revenue was $1.388 billion, down 2% compared to $1.412 billion, prior year. Analysts expected revenue of $1.4 billion, for the quarter.

For 2021, the company now expects adjusted EPS of more than $3.20, which reflects an increase compared to the prior range of $3.10 to $3.20. Revenue growth is anticipated in the mid-single digits.

For second quarter, the company expects adjusted EPS growth of approximately 20%. Revenue growth is projected in the high-single digits.

Cerner also announced that its Board has approved a new share repurchase program, which allows the company to repurchase up to $3.75 billion through Dec. 31, 2023.

Cerner also announced that Brent Shafer and the Board have initiated a process to identify the next CEO. The Board has formed a CEO search committee and has retained a leading executive search firm to launch a market search. Shafer plans to serve as chairman and CEO until the Board has appointed a successor, after which he will serve as a senior advisor for one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hedge-fund billionaire William Ackman's Pershing Square Tontine Holdings Ltd. (PSTH) agreed to acquire 10% of Universal Music Group from French media conglomerate Vivendi (VIV.L, VIVEF.PK) for about $4 billion, the companies said in a statement on Sunday. The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings.
Follow RTT